Language

Dermatology Research

Partnering with Pace Dermatology

We have recently partnered with Pace Dermatology to bring more accessible and innovative dermatology treatments to patients in the South Sound and Pacific Northwest. Together, patients benefit from the research expertise of the MultiCare’s Institute for Research & Innovation and the highly-skilled, passionate clinical team at Pace Dermatology. 

Dermatology studies include, but are not limited to, the following therapeutic areas:

  • Psoriasis
  • Atopic dermatitis
  • Acne
  • And other conditions coming soon

Drs. Aaron and Andrew Pace lead Pace Dermatology – with locations in Tacoma and Lakewood. They are board certified in dermatology, so patients can expect the highest level of care. 

Please click here to learn more about Pace Dermatology.

Dermatology Studies Accepting Participants

Adult 

Acne

Foamix

Study Number: FX2017-22 - A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to- Severe Acne Vulgaris

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6990

Pediatrics

Atopic Dermatitis

Regeneron 1434

Study Number: R668-AD-1434 - An open-label extension study to assess the long-term safety and efficacy of Dupilumab in patients 6 months or older to <18 yers of age with atopic dermatitis.

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992


Regeneron 1539

Study Number: R668-AD-1607 - An open-label, randomized, actual use study of Dupilumab auto-injector device in patients with atopic dermatitis.

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992


Pediatric Atopic Dermatitis

Study Number: B7451012 - A phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of PF-04965842 monotherapy in subjects aged 12 years and older, with moderate to severe atopic dermatitis.

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992

Acne

Foamix Acne Vulgaris

Study Number: FX2017-22- A randomized, double-blind, vehicle-controlled study to evaluate the efficacy and safety of topical administration of FMX101 for 12 weeks in the treatment of moderate to severe acne vulgaris.

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6990